# Collegium Pharmaceutical

Type: Company (COLL)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/collegium-pharmaceutical
Canonical HTML page: https://gethealthbrief.com/entity/collegium-pharmaceutical

## Timeline

- **2026-02-26**: FY 2025 Earnings — Wave and Collegium release full-year financial results and 2026 guidance.
- **2026**: Anticipated Filing — Expected regulatory submission for WVE-N531 in Duchenne muscular dystrophy.
- **2025-Q4**: RNA Editing Milestone — WVE-006 demonstrates successful RNA editing in AATD patients.
- **2025-Q2**: DMD Breakthrough — Wave reports industry-leading dystrophin expression for WVE-N531.

## Recent coverage (3 stories)

### Collegium Pharma EPS Beats by $0.20; Revenue Grows 6.3% to $199.88M
2026-08-09 18:29:04 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Collegium Pharmaceutical's Q2 2026 earnings beat signals sustained demand for its abuse-deterrent pain medications. Revenue grew 6.3% to $199.88M, and EPS of $1.92 surpassed forecasts by $0.20, indicating commercial strength despite regulatory pressures.
Full story: https://gethealthbrief.com/story/collegium-pharma-q2-2026-earnings-health

### Mid-Cap Biotech Earnings: Specialized Platforms Outperform in Q4 2025
2026-02-26 22:32:06 · Sentiment: Neutral · Impact: 5/10 · Sources: 12

The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.
Full story: https://gethealthbrief.com/story/mid-cap-biotech-q4-2025-earnings-intelligence

### Wave Life Sciences and Collegium Report 2025 Results Amid RNA Breakthroughs
2026-02-26 14:24:42 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wave Life Sciences and Collegium Pharmaceutical released their Q4 and full-year 2025 results, highlighting a pivotal year for RNA editing and specialty pain management. Wave's transition toward a commercial-stage biotech is accelerated by its GSK partnership and landmark clinical data in Alpha-1 antitrypsin deficiency.
Full story: https://gethealthbrief.com/story/wave-life-sciences-collegium-2025-financials-rna-editing

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.